BH.IMMUN&BIO | BIOCON | BH.IMMUN&BIO/ BIOCON |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 23.2 | - | View Chart |
P/BV | x | 1.5 | 2.1 | 70.9% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
BH.IMMUN&BIO BIOCON |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
BIOCON Mar-23 |
BH.IMMUN&BIO/ BIOCON |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 388 | 13.4% | |
Low | Rs | 21 | 192 | 10.7% | |
Sales per share (Unadj.) | Rs | 10.3 | 93.1 | 11.1% | |
Earnings per share (Unadj.) | Rs | -3.9 | 5.4 | -72.0% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 14.6 | -26.0% | |
Dividends per share (Unadj.) | Rs | 0 | 1.50 | 0.0% | |
Avg Dividend yield | % | 0 | 0.5 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 146.5 | 13.9% | |
Shares outstanding (eoy) | m | 43.18 | 1,200.60 | 3.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 3.1 | 112.4% | |
Avg P/E ratio | x | -9.4 | 54.1 | -17.3% | |
P/CF ratio (eoy) | x | -9.5 | 19.8 | -47.9% | |
Price / Book Value ratio | x | 1.8 | 2.0 | 89.5% | |
Dividend payout | % | 0 | 28.0 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 347,814 | 0.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 21,810 | 0.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 111,742 | 0.4% | |
Other income | Rs m | 11 | 7,681 | 0.1% | |
Total revenues | Rs m | 457 | 119,423 | 0.4% | |
Gross profit | Rs m | -161 | 16,611 | -1.0% | |
Depreciation | Rs m | 2 | 11,131 | 0.0% | |
Interest | Rs m | 71 | 4,190 | 1.7% | |
Profit before tax | Rs m | -223 | 8,971 | -2.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 2,541 | -2.2% | |
Profit after tax | Rs m | -166 | 6,430 | -2.6% | |
Gross profit margin | % | -36.0 | 14.9 | -242.3% | |
Effective tax rate | % | 25.3 | 28.3 | 89.2% | |
Net profit margin | % | -37.3 | 5.8 | -648.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 123,340 | 0.3% | |
Current liabilities | Rs m | 940 | 85,107 | 1.1% | |
Net working cap to sales | % | -130.6 | 34.2 | -381.6% | |
Current ratio | x | 0.4 | 1.4 | 26.3% | |
Inventory Days | Days | 85 | 129 | 66.2% | |
Debtors Days | Days | 1,135 | 117 | 972.7% | |
Net fixed assets | Rs m | 1,262 | 394,078 | 0.3% | |
Share capital | Rs m | 432 | 6,003 | 7.2% | |
"Free" reserves | Rs m | 450 | 169,926 | 0.3% | |
Net worth | Rs m | 882 | 175,929 | 0.5% | |
Long term debt | Rs m | 0 | 152,905 | 0.0% | |
Total assets | Rs m | 1,620 | 517,418 | 0.3% | |
Interest coverage | x | -2.2 | 3.1 | -68.6% | |
Debt to equity ratio | x | 0 | 0.9 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.2 | 127.5% | |
Return on assets | % | -5.9 | 2.1 | -288.1% | |
Return on equity | % | -18.9 | 3.7 | -516.1% | |
Return on capital | % | -17.2 | 4.0 | -430.8% | |
Exports to sales | % | 0 | 3.1 | 0.0% | |
Imports to sales | % | 14.5 | 6.0 | 242.9% | |
Exports (fob) | Rs m | NA | 3,467 | 0.0% | |
Imports (cif) | Rs m | 65 | 6,654 | 1.0% | |
Fx inflow | Rs m | 0 | 3,467 | 0.0% | |
Fx outflow | Rs m | 65 | 6,654 | 1.0% | |
Net fx | Rs m | -65 | -3,187 | 2.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 18,525 | 0.6% | |
From Investments | Rs m | 5 | -142,818 | -0.0% | |
From Financial Activity | Rs m | -147 | 130,487 | -0.1% | |
Net Cashflow | Rs m | -34 | 6,411 | -0.5% |
Indian Promoters | % | 59.3 | 40.4 | 146.8% | |
Foreign collaborators | % | 0.0 | 20.3 | - | |
Indian inst/Mut Fund | % | 0.0 | 19.3 | - | |
FIIs | % | 0.0 | 5.6 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 39.4 | 103.5% | |
Shareholders | 35,313 | 470,261 | 7.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | Biocon | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | 4.17% | 0.31% |
1-Month | -2.23% | 15.14% | 0.08% |
1-Year | 28.97% | 30.23% | 54.11% |
3-Year CAGR | -13.27% | -6.33% | 14.46% |
5-Year CAGR | 30.36% | 2.09% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the Biocon share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of Biocon the stake stands at 60.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of Biocon.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
Biocon paid Rs 1.5, and its dividend payout ratio stood at 28.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of Biocon.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.